{"content":"<li class=\"n-box-item date-title\" data-end=\"1498276799\" data-start=\"1498190400\" data-txt=\"Monday, December 23, 2019\">Friday, June 23, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3275376\" data-ts=\"1498253782\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275376-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers, as of 5.25 p.m.:</b> <a href='https://seekingalpha.com/symbol/SFM' title='Sprouts Farmers Market'>SFM</a> <font color='green'>+2.2%</font>. <a href='https://seekingalpha.com/symbol/EXEL' title='Exelixis, Inc.'>EXEL</a> <font color='green'>+2.0%</font>. <a href='https://seekingalpha.com/symbol/PTLA' title='Portola Pharmaceuticals'>PTLA</a> <font color='green'>+1.7%</font>. <a href='https://seekingalpha.com/symbol/JASO' title='JA Solar Holdings, Co., Ltd.'>JASO</a> <font color='green'>+1.6%</font>. <a href='https://seekingalpha.com/symbol/FBR' title='Fibria Celulose S.A.'>FBR</a> <font color='green'>+1.4%</font>.</li><li><b>Top losers, as of 5.25p.m.:</b> <a href='https://seekingalpha.com/symbol/CRBP' title='Corbus Pharmaceuticals Holdings, Inc.'>CRBP</a> <font color='red'>-3.9%</font>. <a href='https://seekingalpha.com/symbol/SSI' title='Stage Stores, Inc.'>SSI</a> <font color='red'>-2.7%</font>. <a href='https://seekingalpha.com/symbol/RGCO' title='RGC Resources Inc.'>RGCO</a> <font color='red'>-2.2%</font>. <a href='https://seekingalpha.com/symbol/RL' title='Ralph Lauren Corporation'>RL</a> <font color='red'>-1.1%</font>. <a href='https://seekingalpha.com/symbol/CARA' title='Cara Therapeutics Inc.'>CARA</a> <font color='red'>-1.1%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3275376\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$SFM $EXEL $PTLA - After Hours Gainers / Losers https://seekingalpha.com/news/3275376-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3275376-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275367\" data-ts=\"1498249745\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275367-weekly-etf-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Weekly ETF Gainers / Losers</a></h4><ul>     <li><b>Top gainers:</b> <a href='https://seekingalpha.com/symbol/TAN' title='Guggenheim Solar ETF'>TAN</a> <font color='green'>+8.0%</font>. <a href='https://seekingalpha.com/symbol/IYH' title='iShares U.S. Healthcare ETF'>IYH</a> <font color='green'>+3.7%</font>. <a href='https://seekingalpha.com/symbol/GDXJ' title='VanEck Vectors Junior Gold Miners ETF'>GDXJ</a> <font color='green'>+3.6%</font>. <a href='https://seekingalpha.com/symbol/XLV' title='Health Care Select Sect SPDR ETF'>XLV</a> <font color='green'>+3.6%</font>. <a href='https://seekingalpha.com/symbol/GDX' title='VanEck Vectors Gold Miners ETF'>GDX</a> <font color='green'>+3.1%</font>.</li><li><b>Top losers:</b> <a href='https://seekingalpha.com/symbol/OIL' title='iPath S&P Crude Oil Total Return Index ETN'>OIL</a> <font color='red'>-5.5%</font>. <a href='https://seekingalpha.com/symbol/USO' title='The United States Oil ETF, LP'>USO</a> <font color='red'>-4.1%</font>. <a href='https://seekingalpha.com/symbol/EWA' title='iShares MSCI Australia ETF'>EWA</a> <font color='red'>-3.6%</font>. <a href='https://seekingalpha.com/symbol/BNO' title='The United States Brent Oil ETF, LP'>BNO</a> <font color='red'>-3.6%</font>. <a href='https://seekingalpha.com/symbol/DBA' title='PowerShares DB Agriculture ETF'>DBA</a> <font color='red'>-3.5%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3275367\" data-linked=\"Weekly ETF Gainers / Losers\" data-tweet=\"$TAN $IYH $GDXJ - Weekly ETF Gainers / Losers https://seekingalpha.com/news/3275367-weekly-etf-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3275367-weekly-etf-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:29 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275356\" data-ts=\"1498247872\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EZPW\" target=\"_blank\">EZPW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275356-small-boost-for-ezcorp-rovida-advisors-adds-to-stake\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Small boost for EZCORP as Rovida Advisors adds to stake</a></h4><ul><li>Rovida Advisors takes its stake in EZCORP (<a href='https://seekingalpha.com/symbol/EZPW' title='EZCORP, Inc.'>EZPW</a> <font color='green'>+1.1%</font>) above 5%, <a href=\"https://seekingalpha.com/filing/3603627\" target=\"_blank\">showing ownership of </a>2.6M shares, up from 2.55M shares on March 31.</li></ul><div class=\"tiny-share-widget\" data-id=\"3275356\" data-linked=\"Small boost for EZCORP as Rovida Advisors adds to stake\" data-tweet=\"$EZPW - Small boost for EZCORP as Rovida Advisors adds to stake https://seekingalpha.com/news/3275356-small-boost-for-ezcorp-rovida-advisors-adds-to-stake?source=tweet\" data-url=\"https://seekingalpha.com/news/3275356-small-boost-for-ezcorp-rovida-advisors-adds-to-stake\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:57 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275354\" data-ts=\"1498246510\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NVIV\" target=\"_blank\">NVIV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275354-invivo-sells-off-from-recent-run-up-shares-down-26\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">InVivo sells off from recent run-up; shares down 26%</a></h4><ul><li>Longs in InVivo Therapeutics (<a href='https://seekingalpha.com/symbol/NVIV' title='InVivo Therapeutics Holdings Corp'>NVIV</a> <font color='red'>-26%</font>) are getting cold water in the face today. Shares are down on more than triple normal volume after running up over 80% since last week. The degree of selling appears excessive so investors should be wary of an equity offering or other dilutive event.</li><li>On Tuesday, the company <a href=\"https://seekingalpha.com/pr/16866297-invivo-therapeutics-announces-new-patient-enrollment-inspire-study-allegheny-general-hospital\" target=\"_blank\">announced </a>the 16th participant in the INSPIRE study assessing its Neuro-Spinal Scaffold in patients with complete thoracic AIS A spinal cord injury. Enrollment should be completed next quarter.</li></ul><div class=\"tiny-share-widget\" data-id=\"3275354\" data-linked=\"InVivo sells off from recent run-up; shares down 26%\" data-tweet=\"$NVIV - InVivo sells off from recent run-up; shares down 26% https://seekingalpha.com/news/3275354-invivo-sells-off-from-recent-run-up-shares-down-26?source=tweet\" data-url=\"https://seekingalpha.com/news/3275354-invivo-sells-off-from-recent-run-up-shares-down-26\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275351\" data-ts=\"1498245136\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BCRX\" target=\"_blank\">BCRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275351-biocryst-and-shire-under-pressure-on-fda-approval-of-behrings-hae-med\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Biocryst and Shire under pressure on FDA approval of Behring&#39;s HAE med</a></h4><ul><li>BioCryst Pharmaceuticals (<a href='https://seekingalpha.com/symbol/BCRX' title='BioCryst Pharmaceuticals, Inc.'>BCRX</a> <font color='red'>-1.8%</font>) and Shire plc (<a href='https://seekingalpha.com/symbol/SHPG' title='Shire PLC'>SHPG</a> <font color='red'>-1.5%</font>) are both in the red after the FDA approved CSL Behring's HAEGARDA for the prevention of hereditary angioedema &#40;HAE&#41; attacks.</li><li>BioCryst's HAE candidate is Phase 2-stage BCX7353 and Shire's is registration-stage lanadelumab.</li><li>Lanadelumab is a human monoclonal antibody that binds to (inhibits) an enzyme called&nbsp;<a href=\"https://en.wikipedia.org/wiki/Plasma_kallikrein\" target=\"_blank\">plasma kallikrein</a>&nbsp;that plays a key role in blood pressure regulation, thrombosis and inflammation.</li><li>BCX7353 is a once-daily inhibitor of plasma kallikrein.</li><li>HAEGARDA is a plasma-derived concentrate of C1-esterase inhibitor that targets the root cause of HAE by replacing the deficient C1-INH protein.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3268414-shires-lanadelumab-successful-late-stage-hae-study-shares-ahead-6-percent-premarket\" target=\"_blank\">Shire's lanadelumab successful in late-stage HAE study; shares ahead 6% premarket</a> (May 18)</li></ul><div class=\"tiny-share-widget\" data-id=\"3275351\" data-linked=\"Biocryst and Shire under pressure on FDA approval of Behring&#39;s HAE med\" data-tweet=\"$BCRX $BCRX $SHPG - Biocryst and Shire under pressure on FDA approval of Behring&#39;s HAE med https://seekingalpha.com/news/3275351-biocryst-and-shire-under-pressure-on-fda-approval-of-behrings-hae-med?source=tweet\" data-url=\"https://seekingalpha.com/news/3275351-biocryst-and-shire-under-pressure-on-fda-approval-of-behrings-hae-med\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:12 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275347\" data-ts=\"1498244409\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275347-technology-top-gainers-losers-of-3-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 3:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/SNCR' title='Synchronoss Technologies, Inc.'>SNCR</a> <font color='green'>+34%</font>. <a href='https://seekingalpha.com/symbol/QUIK' title='QuickLogic Corporation'>QUIK</a> <font color='green'>+27%</font>. <a href='https://seekingalpha.com/symbol/MVIS' title='Microvision, Inc.'>MVIS</a> <font color='green'>+12%</font>. COOL <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/JMU' title='JMU Limited'>JMU</a> <font color='green'>+11%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/PRKR' title='ParkerVision, Inc.'>OTC:PRKR</a> <font color='red'>-18%</font>. BBRY <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/AMSWA' title='American Software, Inc.'>AMSWA</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/NH' title='NantHealth'>NH</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/STRM' title='Streamline Health Solutions, Inc.'>STRM</a> <font color='red'>-6%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3275347\" data-linked=\"Technology - Top Gainers / Losers as of 3:00 pm\" data-tweet=\"$SNCR $QUIK $MVIS - Technology - Top Gainers / Losers as of 3:00 pm https://seekingalpha.com/news/3275347-technology-top-gainers-losers-of-3-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3275347-technology-top-gainers-losers-of-3-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275338\" data-ts=\"1498240896\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SAFM\" target=\"_blank\">SAFM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275338-sanderson-farms-issues-statement-on-lawsuit\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sanderson Farms issues statement on lawsuit</a></h4><ul> <li>Sanderson Farms (<a href='https://seekingalpha.com/symbol/SAFM' title='Sanderson Farms, Inc.'>SAFM</a> <font color='green'>+0.8%</font>)&nbsp;reacts to allegations raised in a lawsuit filed in California.</li><li>Key statement: \"The       Company unequivocally states it does not administer the antibiotics,       other chemicals and pesticides, or 'other pharmaceuticals' listed in the       complaint to its flocks, with one exception. To suggest otherwise is       false and irresponsible.\"</li><li>Sanderson notes that in its 70-year history it&nbsp;has never been cited by the United States Department of Agriculture or any other regulatory body for a residue violation.</li><li>Source: <a href=\"https://seekingalpha.com/pr/16870718-sanderson-farms-comments-california-complaint\" target=\"_blank\">Press Release</a></li><li>Previously: <a href=\"https://seekingalpha.com/news/3275126-sanderson-farms-faces-consumer-lawsuit-alleging-ketamine-found-chicken\" target=\"_blank\">Sanderson Farms faces consumer lawsuit alleging ketamine found in chicken</a> (June 22)</li></ul><div class=\"tiny-share-widget\" data-id=\"3275338\" data-linked=\"Sanderson Farms issues statement on lawsuit\" data-tweet=\"$SAFM - Sanderson Farms issues statement on lawsuit https://seekingalpha.com/news/3275338-sanderson-farms-issues-statement-on-lawsuit?source=tweet\" data-url=\"https://seekingalpha.com/news/3275338-sanderson-farms-issues-statement-on-lawsuit\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275339\" data-ts=\"1498240839\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275339-energy-materials-top-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top Gainers / Losers as of 2:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/ASIX' title='AdvanSix Inc.'>ASIX</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/PKD-OLD' title='Parker Drilling Company'>PKD-OLD</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/AKS' title='AK Steel Holding Corp'>AKS</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/CENX' title='Century Aluminum Company'>CENX</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/IPI' title='Intrepid Potash, Inc.'>IPI</a> <font color='green'>+7%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/PED' title='PEDEVCO Corp.'>PED</a> <font color='red'>-32%</font>. <a href='https://seekingalpha.com/symbol/HOS' title='Hornbeck Offshore Services, Inc.'>HOS</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/ERN' title='Erin Energy Corp.'>ERN</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/NOG' title='Northern Oil & Gas, Inc'>NOG</a> <font color='red'>-10%</font>. SGY <font color='red'>-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3275339\" data-linked=\"Energy/Materials - Top Gainers / Losers as of 2:00 pm\" data-tweet=\"$ASIX $PKD $AKS - Energy/Materials - Top Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3275339-energy-materials-top-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3275339-energy-materials-top-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275335\" data-ts=\"1498240499\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HD\" target=\"_blank\">HD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275335-home-improvement-stocks-trail-off-after-data-releases\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Home improvement stocks trail off after data releases</a></h4><ul><li>Home Depot (<a href='https://seekingalpha.com/symbol/HD' title='Home Depot, Inc.'>HD</a> <font color='red'>-2.3%</font>) and Lowe's (<a href='https://seekingalpha.com/symbol/LOW' title='Lowe&#39;s Companies, Inc.'>LOW</a> <font color='red'>-2.1%</font>)&nbsp;trade weak after U.S. housing data shows higher prices and tighter supply.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3275323-new-home-sales-trend-says-strong\" target=\"_blank\">New home sales: Trend says strong</a> (June 23)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3275023-fhfa-housing-price-index-higher-hoped-april\" target=\"_blank\">FHFA Housing Price index higher than hoped in April</a> (June 22)</li></ul><div class=\"tiny-share-widget\" data-id=\"3275335\" data-linked=\"Home improvement stocks trail off after data releases\" data-tweet=\"$HD $HD $LOW - Home improvement stocks trail off after data releases https://seekingalpha.com/news/3275335-home-improvement-stocks-trail-off-after-data-releases?source=tweet\" data-url=\"https://seekingalpha.com/news/3275335-home-improvement-stocks-trail-off-after-data-releases\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:54 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>25&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275333\" data-ts=\"1498239510\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275333-financials-top-5-gainers-losers-of-1-35pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:35PM</a></h4><ul>     <li><strong>Gainers:</strong> <a href='https://seekingalpha.com/symbol/FOR' title='Forestar Group Inc.'>FOR</a>&nbsp;<font color='green'>+8%</font>.</li>     <li><strong>Losers:</strong>&nbsp;<a href='https://seekingalpha.com/symbol/PN' title='Patriot National, Inc.'>PN</a>&nbsp;<font color='red'>-13%.</font></li> </ul><div class=\"tiny-share-widget\" data-id=\"3275333\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:35PM\" data-tweet=\"$FOR $PN - Financials - Top 5 Gainers / Losers as of 1:35PM https://seekingalpha.com/news/3275333-financials-top-5-gainers-losers-of-1-35pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3275333-financials-top-5-gainers-losers-of-1-35pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:38 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275331\" data-ts=\"1498238872\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLLS\" target=\"_blank\">CLLS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275331-cellectis-gene-editing-ag-unit-readies-ipo-shares-up-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cellectis gene-editing ag unit readies IPO; shares up 2%</a></h4><ul><li>Cellectis (<a href='https://seekingalpha.com/symbol/CLLS' title='Cellectis S.A.'>CLLS</a> <font color='green'>+2.3%</font>) <a href=\"https://seekingalpha.com/pr/16870684-calyxt-files-registration-statement-proposed-initial-public-offering\" target=\"_blank\">announces </a>that its wholly owned gene-editing agriculture company, <a href=\"http://www.calyxt.com/\" target=\"_blank\">Calyxt</a>, has filed an <a href=\"https://www.sec.gov/Archives/edgar/data/1705843/000119312517211349/d370817ds1.htm\" target=\"_blank\">S-1</a> with the SEC in preparation for an IPO. Number of shares and expected price range have yet to be determined.</li></ul><div class=\"tiny-share-widget\" data-id=\"3275331\" data-linked=\"Cellectis gene-editing ag unit readies IPO; shares up 2%\" data-tweet=\"$CLLS - Cellectis gene-editing ag unit readies IPO; shares up 2% https://seekingalpha.com/news/3275331-cellectis-gene-editing-ag-unit-readies-ipo-shares-up-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3275331-cellectis-gene-editing-ag-unit-readies-ipo-shares-up-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:27 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275330\" data-ts=\"1498238665\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MS\" target=\"_blank\">MS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275330-banks-head-lower-after-cruising-through-stress-tests\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Banks head lower after cruising through stress tests</a></h4><ul><li>The good news no doubt priced in prior to last night, the banking sector (<a href='https://seekingalpha.com/symbol/KBE' title='SPDR S&P Bank ETF'>KBE</a> <font color='red'>-0.7%</font>), (<a href='https://seekingalpha.com/symbol/KRE' title='SPDR S&P Regional Banking ETF'>KRE</a> <font color='red'>-0.8%</font>) is underperforming <a href=\"https://seekingalpha.com/news/3275165-banks-pass-years-stress-tests\" target=\"_blank\">after all 34 lenders</a> passed the Fed's stress tests.</li><li>Having the roughest session today is Morgan Stanley (<a href='https://seekingalpha.com/symbol/MS' title='Morgan Stanley'>MS</a> <font color='red'>-2%</font>) after it came closet to failing on the supplementary leverage ratio in the Fed's severely adverse scenario. Macquarie is out with a note calling the decline a buying opportunity.</li><li>Investors can now look forward to next week's release of the CCAR results, at which lenders' capital return plans will or won't be approved (or somewhere in between).</li><li>U.S. Bancorp (<a href='https://seekingalpha.com/symbol/USB' title='U.S. Bancorp'>USB</a> <font color='red'>-1.1%</font>), Regions Financial (<a href='https://seekingalpha.com/symbol/RF' title='Regions Financial Corporation'>RF</a> <font color='red'>-1.3%</font>), KeyCorp (<a href='https://seekingalpha.com/symbol/KEY' title='KeyCorp'>KEY</a> <font color='red'>-1.6%</font>), PNC Financial (<a href='https://seekingalpha.com/symbol/PNC' title='PNC Financial Services Group, Inc.'>PNC</a> <font color='red'>-1%</font>), Fifth Third (<a href='https://seekingalpha.com/symbol/FITB' title='Fifth Third Bancorp'>FITB</a> <font color='red'>-1.8%</font>)</li><li>ETFs: <a href='https://seekingalpha.com/symbol/XLF' title='Financial Select Sector SPDR ETF'>XLF</a>, <a href='https://seekingalpha.com/symbol/FAS' title='Direxion Daily Financial Bull 3x Shares ETF'>FAS</a>, <a href='https://seekingalpha.com/symbol/FAZ' title='Direxion Daily Financial Bear 3x Shares ETF'>FAZ</a>, <a href='https://seekingalpha.com/symbol/KRE' title='SPDR S&P Regional Banking ETF'>KRE</a>, <a href='https://seekingalpha.com/symbol/VFH' title='Vanguard Financials ETF'>VFH</a>, <a href='https://seekingalpha.com/symbol/UYG' title='ProShares Ultra Financials ETF'>UYG</a>, <a href='https://seekingalpha.com/symbol/KBE' title='SPDR S&P Bank ETF'>KBE</a>, <a href='https://seekingalpha.com/symbol/IYF' title='iShares U.S. Financials ETF'>IYF</a>, <a href='https://seekingalpha.com/symbol/FNCL' title='Fidelity MSCI Financials Index ETF'>FNCL</a>, <a href='https://seekingalpha.com/symbol/BTO' title='John Hancock Financial Opportunity Fund'>BTO</a>, <a href='https://seekingalpha.com/symbol/IAT' title='iShares U.S. Regional Banks ETF'>IAT</a>, <a href='https://seekingalpha.com/symbol/IYG' title='iShares U.S. Financial Services ETF'>IYG</a>, <a href='https://seekingalpha.com/symbol/KBWB' title='Invesco KBW Bank Portfolio ETF'>KBWB</a>, <a href='https://seekingalpha.com/symbol/QABA' title='First Trust Nasdaq ABA Community Bank ETF'>QABA</a>, <a href='https://seekingalpha.com/symbol/FXO' title='First Trust Financials AlphaDEX ETF'>FXO</a>, <a href='https://seekingalpha.com/symbol/SEF' title='ProShares Short Financials ETF'>SEF</a>, <a href='https://seekingalpha.com/symbol/KBWR' title='Invesco KBW Regional Banking Portfolio ETF'>KBWR</a>, <a href='https://seekingalpha.com/symbol/RYF' title='Invesco S&P Equal Weight Financial ETF'>RYF</a>, <a href='https://seekingalpha.com/symbol/FINU' title='ProShares UltraPro Financials ETF'>FINU</a>, <a href='https://seekingalpha.com/symbol/XLFS' title='Financial Services Select Sector SPDR ETF'>XLFS</a>, <a href='https://seekingalpha.com/symbol/DPST' title='Direxion Daily Regional Banks Bull 3x Shares ETF'>DPST</a>, <a href='https://seekingalpha.com/symbol/KRU' title='ProShares Ultra S&P Regional Banking ETF'>KRU</a>, <a href='https://seekingalpha.com/symbol/FINZ' title='ProShares UltraPro Short Financials ETF'>FINZ</a>, <a href='https://seekingalpha.com/symbol/RWW' title='Oppenheimer Financials Sector Revenue ETF'>RWW</a>, <a href='https://seekingalpha.com/symbol/WDRW' title='Direxion Daily Regional Banks Bear 3x Shares ETF'>WDRW</a>, <a href='https://seekingalpha.com/symbol/KRS' title='ProShares Short S&P Regional Banking ETF'>KRS</a>, <a href='https://seekingalpha.com/symbol/FAZZ' title='Direxion Daily Financial Bear 1x Shares ETF'>FAZZ</a>, <a href='https://seekingalpha.com/symbol/JHMF' title='John Hancock Multifactor Financials ETF'>JHMF</a>, <a href='https://seekingalpha.com/symbol/FTXO' title='First Trust Nasdaq Bank ETF'>FTXO</a>, <a href='https://seekingalpha.com/symbol/FNCF' title='iShares Edge MSCI Multifactor Financials ETF'>FNCF</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3275330\" data-linked=\"Banks head lower after cruising through stress tests\" data-tweet=\"$MS $KBE $KRE - Banks head lower after cruising through stress tests https://seekingalpha.com/news/3275330-banks-head-lower-after-cruising-through-stress-tests?source=tweet\" data-url=\"https://seekingalpha.com/news/3275330-banks-head-lower-after-cruising-through-stress-tests\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:24 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275329\" data-ts=\"1498237968\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NVO\" target=\"_blank\">NVO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275329-novo-to-investigate-weight-loss-effect-of-glpminus-1-analogue-semaglutide-late-stage-study-on\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Novo to investigate weight loss effect of GLP-1 analogue semaglutide, late-stage study on tap next year; shares ahead 2%</a></h4><ul><li>Buoyed by the weight loss effects observed in earlier studies of once-weekly diabetes med semaglutide, Novo Nordisk (<a href='https://seekingalpha.com/symbol/NVO' title='Novo Nordisk A/S'>NVO</a> <font color='green'>+1.8%</font>) plans to initiate a Phase 3 study next year to prove its effect in inducing and maintaining weight loss in obese people.</li><li>Clinical trials assessing the GLP-1 analogue in type 2 diabetics showed an average weight loss of ~14% versus 2% for placebo, diet and exercise.</li><li>Source: Bloomberg First Word</li></ul><div class=\"tiny-share-widget\" data-id=\"3275329\" data-linked=\"Novo to investigate weight loss effect of GLP-1 analogue semaglutide, late-stage study on tap next year; shares ahead 2%\" data-tweet=\"$NVO - Novo to investigate weight loss effect of GLP-1 analogue semaglutide, late-stage study on tap next year; shares ahead 2% https://seekingalpha.com/news/3275329-novo-to-investigate-weight-loss-effect-of-glpminus-1-analogue-semaglutide-late-stage-study-on?source=tweet\" data-url=\"https://seekingalpha.com/news/3275329-novo-to-investigate-weight-loss-effect-of-glpminus-1-analogue-semaglutide-late-stage-study-on\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:12 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275325\" data-ts=\"1498236370\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275325-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/SNCR' title='Synchronoss Technologies, Inc.'>SNCR</a> <font color='green'>+35%</font>. <a href='https://seekingalpha.com/symbol/RWLK' title='ReWalk Robotics'>RWLK</a> <font color='green'>+33%</font>. <a href='https://seekingalpha.com/symbol/QUIK' title='QuickLogic Corporation'>QUIK</a> <font color='green'>+26%</font>. COOL <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/CVRS' title='Corindus Vascular Robotics, Inc.'>CVRS</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/IMDZ' title='Immune Design'>IMDZ</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/SGOC' title='SGOCO Techn'>SGOC</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/CARA' title='Cara Therapeutics Inc.'>CARA</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/GLYC' title='GlycoMimetics'>GLYC</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/ASND' title='Ascendis Pharma'>ASND</a> <font color='green'>+10%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/TOPS' title='TOP Ships Inc.'>TOPS</a> <font color='red'>-59%</font>. <a href='https://seekingalpha.com/symbol/PED' title='PEDEVCO Corp.'>PED</a> <font color='red'>-31%</font>. <a href='https://seekingalpha.com/symbol/DCTH' title='Delcath Systems, Inc.'>OTC:DCTH</a> <font color='red'>-29%</font>. <a href='https://seekingalpha.com/symbol/PRKR' title='ParkerVision, Inc.'>OTC:PRKR</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/NVIV' title='InVivo Therapeutics Holdings Corp'>NVIV</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/ERN' title='Erin Energy Corp.'>ERN</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/OCUL' title='Ocular Therapeutix'>OCUL</a> <font color='red'>-12%</font>. BBRY <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/BBBY' title='Bed Bath & Beyond Inc.'>BBBY</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/PN' title='Patriot National, Inc.'>PN</a> <font color='red'>-11%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3275325\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$SNCR $RWLK $QUIK - Midday Gainers / Losers https://seekingalpha.com/news/3275325-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3275325-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:46 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275324\" data-ts=\"1498236185\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/V\" target=\"_blank\">V</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275324-cowen-sees-explosion-of-visa-acceptance-locations\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cowen sees &#39;explosion&#39; of Visa acceptance locations</a></h4><ul><li>Cowen walks away from Visa's (<a href='https://seekingalpha.com/symbol/V' title='Visa Inc.'>V</a> <font color='green'>+1.6%</font>) analyst day event convinced that the payments company will be able to <a href=\"https://www.streetinsider.com/Analyst+Comments/Visa+%28V%29%3A+Investor+Day+Highlights+Digital+Explosion+-+Cowen/13039010.html\" target=\"_blank\">generate</a> high single-digit or low double-digit revenue growth over the long term.</li><li>Visa is seen benefiting from the \"explosion\" of card acceptance locations.</li><li>Shares are rated at Outperform by Cowen and tagged with a price target of $105.</li><li>Visa is +22.3% YTD.</li></ul><div class=\"tiny-share-widget\" data-id=\"3275324\" data-linked=\"Cowen sees &#39;explosion&#39; of Visa acceptance locations\" data-tweet=\"$V - Cowen sees &#39;explosion&#39; of Visa acceptance locations https://seekingalpha.com/news/3275324-cowen-sees-explosion-of-visa-acceptance-locations?source=tweet\" data-url=\"https://seekingalpha.com/news/3275324-cowen-sees-explosion-of-visa-acceptance-locations\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:43 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>29&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275322\" data-ts=\"1498235602\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PTLA\" target=\"_blank\">PTLA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275322-fda-oks-portolas-anticoagulant-betrixaban-shares-up-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA OKs Portola&#39;s anticoagulant betrixaban; shares up 1%</a></h4><ul><li>The FDA <a href=\"https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm564422.htm\" target=\"_blank\">approves </a>Portola Pharmaceuticals' (<a href='https://seekingalpha.com/symbol/PTLA' title='Portola Pharmaceuticals'>PTLA</a> <font color='green'>+0.5%</font>) BEVYXXA (betrixaban), an extended-duration anticoagulant, for the prevention of venous thromboembolism &#40;VTE&#41; in hospitalized at-risk adult patients.</li><li>The agency's action date was tomorrow (meaning today).</li><li>Previously: <a href=\"https://seekingalpha.com/news/3232453-portola-pharma-plus-20-percent-betrixaban-nda-accepted-priority-review\" target=\"_blank\">Portola Pharma +20% as betrixaban NDA accepted for priority review</a> (Dec. 23, 2016)</li><li><strong>Update</strong>: Shares are up&nbsp;<font color='green'>42%</font>&nbsp;on a 8x surge in volume since trading halt lifted.</li></ul><div class=\"tiny-share-widget\" data-id=\"3275322\" data-linked=\"FDA OKs Portola&#39;s anticoagulant betrixaban; shares up 1%\" data-tweet=\"$PTLA - FDA OKs Portola&#39;s anticoagulant betrixaban; shares up 1% https://seekingalpha.com/news/3275322-fda-oks-portolas-anticoagulant-betrixaban-shares-up-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3275322-fda-oks-portolas-anticoagulant-betrixaban-shares-up-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:33 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>63&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275315\" data-ts=\"1498233705\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275315-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/SGOC' title='SGOCO Techn'>SGOC</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/LFVN' title='LifeVantage Corporation'>LFVN</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/AVP' title='Avon Products, Inc.'>AVP</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/BMS' title='Bemis Company, Inc.'>BMS</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/NLS' title='Nautilus, Inc.'>NLS</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/WKHS' title='Workhorse Group Inc.'>WKHS</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/NBEV' title='New Age Beverages Corporation'>NBEV</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3275315\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$SGOC $LFVN $AVP - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3275315-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3275315-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275314\" data-ts=\"1498233663\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TOSBF\" target=\"_blank\">TOSBF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275314-toshiba-offers-to-talk-western-digital-regarding-chip-unit-sale\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Toshiba offers to talk with Western Digital regarding chip unit sale</a></h4><ul><li>        Toshiba (<a href='https://seekingalpha.com/symbol/TOSBF' title='Toshiba Corp.'>OTCPK:TOSBF</a>, <a href='https://seekingalpha.com/symbol/TOSYY' title='Toshiba Corp. ADR'>OTCPK:TOSYY</a>) <a href=\"https://www.reuters.com/article/us-toshiba-accounting-idUSKBN19D2YW\" target=\"_blank\">offers</a> to speak with Western Digital (NYSE:<a href='https://seekingalpha.com/symbol/WDC' title='Western Digital Corporation'>WDC</a>) regarding the potential $18B sale of Toshiba&rsquo;s chip unit, which Western Digital has fought in court.</li><li>               Western Digital has a stake in the chip unit thanks to its SanDisk acquisition and says Toshiba can&rsquo;t sell the unit without the stakeholder&rsquo;s permission. </li><li>Toshiba rejected Western Digital's bid for the unit.&nbsp;</li><li>               Earlier this week, Toshiba selected a Japan-backed consortium as the bid winner, but Western Digital vowed to keep up the legal fight.&nbsp;</li><li>               The consortium has reportedly offered Western Digital a role, which Toshiba supports but refuses to become the first to say so on the record.&nbsp;</li><li>               Western Digital shares are&nbsp;<font color='green'>up 4.76%</font>.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3275026-reuters-tech-industry-casts-doubts-toshiba-s-lead-chip-unit-bidder\" target=\"_blank\">Reuters: Tech industry casts doubts on Toshiba&rsquo;s lead chip unit bidder</a> (June 22)</li></ul><div class=\"tiny-share-widget\" data-id=\"3275314\" data-linked=\"Toshiba offers to talk with Western Digital regarding chip unit sale\" data-tweet=\"$TOSBF $TOSBF $TOSYY - Toshiba offers to talk with Western Digital regarding chip unit sale https://seekingalpha.com/news/3275314-toshiba-offers-to-talk-western-digital-regarding-chip-unit-sale?source=tweet\" data-url=\"https://seekingalpha.com/news/3275314-toshiba-offers-to-talk-western-digital-regarding-chip-unit-sale\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275310\" data-ts=\"1498232041\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NURO\" target=\"_blank\">NURO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275310-neurometrix-says-clinical-studies-back-pain-relief-benefit-from-quell-shares-ahead-3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NeuroMetrix says clinical studies back pain-relief benefit from Quell; shares ahead 3%</a></h4><ul><li>Thinly traded nano cap NeuroMetrix (<a href='https://seekingalpha.com/symbol/NURO' title='NeuroMetrix, Inc.'>NURO</a> <font color='green'>+3.2%</font>) perks up on light volume on the heels of its <a href=\"https://seekingalpha.com/pr/16870616-neurometrix-provides-update-quell-wearable-pain-relief-clinical-program\" target=\"_blank\">update </a>on clinical programs designed to credential the benefits of wearable pain-relief device Quell.</li><li>In a study published last year, 81% of wearers reported a general improvement in chronic pain while 2/3 reduced their pain medications after using Quell for 60 days.</li><li>There are four ongoing studies: one in chemo-induced peripheral neuropathy, one in cancer, one in low back pain and one comparing Quell to polysomnography (sleep study) in sleep/wake classification and periodic leg movement detection.</li></ul><div class=\"tiny-share-widget\" data-id=\"3275310\" data-linked=\"NeuroMetrix says clinical studies back pain-relief benefit from Quell; shares ahead 3%\" data-tweet=\"$NURO - NeuroMetrix says clinical studies back pain-relief benefit from Quell; shares ahead 3% https://seekingalpha.com/news/3275310-neurometrix-says-clinical-studies-back-pain-relief-benefit-from-quell-shares-ahead-3?source=tweet\" data-url=\"https://seekingalpha.com/news/3275310-neurometrix-says-clinical-studies-back-pain-relief-benefit-from-quell-shares-ahead-3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:34 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275286\" data-ts=\"1498230110\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275286-healthcare-top-5-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 am</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/RWLK' title='ReWalk Robotics'>RWLK</a> <font color='green'>+25%</font>. <a href='https://seekingalpha.com/symbol/CARA' title='Cara Therapeutics Inc.'>CARA</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/MNKD' title='MannKind Corporation'>MNKD</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/GLYC' title='GlycoMimetics'>GLYC</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/OBSV' title='ObsEva'>OBSV</a> <font color='green'>+9%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/NVIV' title='InVivo Therapeutics Holdings Corp'>NVIV</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/OCUL' title='Ocular Therapeutix'>OCUL</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/CLSN' title='Celsion Corporation'>CLSN</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/BLUE' title='bluebird bio, Inc.'>BLUE</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/SBBP' title='Strongbridge Biopharma'>SBBP</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3275286\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 am\" data-tweet=\"$RWLK $CARA $MNKD - Healthcare - Top 5 Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3275286-healthcare-top-5-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3275286-healthcare-top-5-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:01 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275302\" data-ts=\"1498229591\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IMTV\" target=\"_blank\">IMTV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275302-imagination-tv-annouces-debt-restructuring\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Imagination TV annouces debt restructuring</a></h4><ul> <li>Imagination TV (<a href='https://seekingalpha.com/symbol/IMTV' title='Imagination TV, Inc.'>OTCPK:IMTV</a> <font color='green'>+200%</font>) announces the first phase of its plan to restructure the company's debt is underway.</li><li>The website operator says it reached an agreement with debt holders to adjust certain conversion features of $50K of debt.</li><li>Source: <a href=\"https://seekingalpha.com/pr/16870596-imagination-tv-inc-begins-debt-restructuring\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3275302\" data-linked=\"Imagination TV annouces debt restructuring\" data-tweet=\"$IMTV - Imagination TV annouces debt restructuring https://seekingalpha.com/news/3275302-imagination-tv-annouces-debt-restructuring?source=tweet\" data-url=\"https://seekingalpha.com/news/3275302-imagination-tv-annouces-debt-restructuring\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:53 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275297\" data-ts=\"1498227786\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/USFD\" target=\"_blank\">USFD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275297-food-suppliers-slump-amazon-risk-factored-in\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Food suppliers slump as Amazon risk factored in</a></h4><ul><li>US Foods (<a href='https://seekingalpha.com/symbol/USFD' title='US Foods Holding'>USFD</a> <font color='red'>-5.4%</font>), Sysco (<a href='https://seekingalpha.com/symbol/SYY' title='Sysco Corporation'>SYY</a> <font color='red'>-4.3%</font>) and Performance Food Group (<a href='https://seekingalpha.com/symbol/PFGC' title='Performance Food Group'>PFGC</a> <font color='red'>-5%</font>) are all lower after JPMorgan expounds on the risk to food suppliers from Amazon.</li><li>The firm suggests that a risk premium needs to be applied to the sector due to the risk of Amazon jumping into food distribution through a partnership.</li><li>Source: Bloomberg</li><li>The sell-off extends on a down trend for the sector since the Amazon-Whole Foods merger was first announced.</li></ul><div class=\"tiny-share-widget\" data-id=\"3275297\" data-linked=\"Food suppliers slump as Amazon risk factored in\" data-tweet=\"$USFD $USFD $SYY - Food suppliers slump as Amazon risk factored in https://seekingalpha.com/news/3275297-food-suppliers-slump-amazon-risk-factored-in?source=tweet\" data-url=\"https://seekingalpha.com/news/3275297-food-suppliers-slump-amazon-risk-factored-in\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>21&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275295\" data-ts=\"1498227102\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GLCNF\" target=\"_blank\">GLCNF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275295-glencore-lifts-bid-for-rio-tinitos-australian-coal-assets\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Glencore lifts bid for Rio Tinito&#39;s Australian coal assets</a></h4><ul><li>The all-cash offer from Glencore (<a href='https://seekingalpha.com/symbol/GLCNF' title='Glencore Plc'>OTCPK:GLCNF</a>, <a href='https://seekingalpha.com/symbol/GLNCY' title='Glencore Plc ADR'>OTCPK:GLNCY</a>) is now $2.68B, and it comes after Rio Tinto (<a href='https://seekingalpha.com/symbol/RIO' title='Rio Tinto plc'>RIO</a> <font color='green'>+1%</font>) earlier <a href=\"https://seekingalpha.com/news/3274425-rio-tinto-chooses-2_45b-yancoal-offer-coal-mines-glencore-bid\" target=\"_blank\">this week turned</a> down Glencore's $2.5B bid for one for $2.45B from China's Yancoal (<a href='https://seekingalpha.com/symbol/YACAF' title='Yancoal Australia Ltd'>OTC:YACAF</a>, <a href='https://seekingalpha.com/symbol/YZC' title='Yanzhou Coal Mining Co. Ltd.'>YZC</a>).</li><li>Source: <em><a href=\"https://www.wsj.com/articles/glencore-raises-offer-for-rio-tintos-australian-coal-assets-1498225944?mod=e2tw\" target=\"_blank\">WSJ</a></em></li></ul><div class=\"tiny-share-widget\" data-id=\"3275295\" data-linked=\"Glencore lifts bid for Rio Tinito&#39;s Australian coal assets\" data-tweet=\"$GLCNF $GLCNF $GLNCY - Glencore lifts bid for Rio Tinito&#39;s Australian coal assets https://seekingalpha.com/news/3275295-glencore-lifts-bid-for-rio-tinitos-australian-coal-assets?source=tweet\" data-url=\"https://seekingalpha.com/news/3275295-glencore-lifts-bid-for-rio-tinitos-australian-coal-assets\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:11 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275291\" data-ts=\"1498226771\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BKS\" target=\"_blank\">BKS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275291-post-earnings-rally-in-barnes-noble-extends\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Post-earnings rally in Barnes &amp; Noble extends</a></h4><ul><li>Barnes &amp; Noble (NYSE:<a href='https://seekingalpha.com/symbol/BKS' title='Barnes & Noble Inc'>BKS</a>)&nbsp;<font color='green'>shoots up 7.85%</font>&nbsp;as investors continue to snap up shares following the company's smaller-than-expected quarterly loss.</li><li>There's been some rumblings that Amazon's brick-and-mortar play with Whole Foods could entice another buyer to look at B&amp;N with its high-profile retail footprint.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3275019-barnes-and-noble-plus-3-percent-fq4-earnings-revenues-beat-estimates\" target=\"_blank\">Barnes &amp; Noble +3% as FQ4 earnings, revenues beat estimates</a> (June 22)</li></ul><div class=\"tiny-share-widget\" data-id=\"3275291\" data-linked=\"Post-earnings rally in Barnes &amp; Noble extends\" data-tweet=\"$BKS - Post-earnings rally in Barnes &amp; Noble extends https://seekingalpha.com/news/3275291-post-earnings-rally-in-barnes-noble-extends?source=tweet\" data-url=\"https://seekingalpha.com/news/3275291-post-earnings-rally-in-barnes-noble-extends\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:06 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275284\" data-ts=\"1498225636\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ETSY\" target=\"_blank\">ETSY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275284-etsy-jumps-on-talk-of-pe-interest\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Etsy jumps on talk of PE interest</a></h4><ul><li>Etsy (<a href='https://seekingalpha.com/symbol/ETSY' title='Etsy, Inc.'>ETSY</a> <font color='green'>+1.4%</font>) jumps after DealReporter says the company was approached by private equity firms.</li><li>The development is interesting given that earlier this week Etsy reduced its global headcount by about 15%.</li><li>Shares of Etsy are up 51% over the last 52 weeks.</li></ul><div class=\"tiny-share-widget\" data-id=\"3275284\" data-linked=\"Etsy jumps on talk of PE interest\" data-tweet=\"$ETSY - Etsy jumps on talk of PE interest https://seekingalpha.com/news/3275284-etsy-jumps-on-talk-of-pe-interest?source=tweet\" data-url=\"https://seekingalpha.com/news/3275284-etsy-jumps-on-talk-of-pe-interest\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:47 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275277\" data-ts=\"1498225443\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BLUE\" target=\"_blank\">BLUE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275277-preliminary-late-stage-data-on-bluebirds-lentiglobin-underwhelms-investors-shares-off-11\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Preliminary late-stage data on bluebird&#39;s LentiGlobin underwhelms investors; shares off 11%</a></h4><ul><li>Gene therapy developer bluebird bio (<a href='https://seekingalpha.com/symbol/BLUE' title='bluebird bio, Inc.'>BLUE</a> <font color='red'>-11.1%</font>) slumps out the blocks as investors head for exits after the company <a href=\"https://seekingalpha.com/pr/16870358-bluebird-bio-announces-early-data-phase-3-northstarminus-2-hgbminus-207-study-lentiglobintm\" target=\"_blank\">released preliminary data</a> from the Phase 3 <a href=\"https://clinicaltrials.gov/ct2/show/NCT02906202?term=bluebird+bio&amp;titles=lentiglobin&amp;rank=4\" target=\"_blank\">Northstar-2</a> study assessing its LentiGlobin drug product in patients with transfusion-dependent beta thalassemia and non-&beta;<sup>0</sup>/&beta;<sup>0&nbsp;</sup>genotypes. The results will be presented at the European Hematology Association Annual Meeting in Madrid.</li><li>The primary endpoint of the 15-subject trial is the proportion of patients who achieve transfusion independence as defined by total hemoglobin levels of at least 9 g/dL without any red blood cell transfusions for a continuous period of at least 12 months at any time during the study.</li><li>As of June 2, LentiGlobin had been manufactured for six patients using an improved process aimed at increasing vector copy number &#40;VCN&#41; and the percentage of cells successfully transduced.</li><li>Data are presented on the first three patients, but the hemoglobin value is only presented for patient #1 (13.3) at month 6. Follow-up of the other two patients was not sufficient to be clinically relevant.</li><li>According to ClinicalTrials.gov, the primary completion date of the study is January 2020.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3230525-dosing-underway-bluebirds-late-stage-study-lentiglobin-beta-thalassemia\" target=\"_blank\">Dosing underway in bluebird's late-stage study of LentiGlobin in beta thalassemia</a> (Dec. 14, 2016)</li></ul><div class=\"tiny-share-widget\" data-id=\"3275277\" data-linked=\"Preliminary late-stage data on bluebird&#39;s LentiGlobin underwhelms investors; shares off 11%\" data-tweet=\"$BLUE - Preliminary late-stage data on bluebird&#39;s LentiGlobin underwhelms investors; shares off 11% https://seekingalpha.com/news/3275277-preliminary-late-stage-data-on-bluebirds-lentiglobin-underwhelms-investors-shares-off-11?source=tweet\" data-url=\"https://seekingalpha.com/news/3275277-preliminary-late-stage-data-on-bluebirds-lentiglobin-underwhelms-investors-shares-off-11\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:44 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275276\" data-ts=\"1498224234\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DHI\" target=\"_blank\">DHI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275276-d-r-horton-lifts-bid-for-forestar-group\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">D.R. Horton lifts bid for Forestar Group</a></h4><ul><li>D.R. Horton (NYSE:<a href='https://seekingalpha.com/symbol/DHI' title='D. R. Horton Inc.'>DHI</a>) is <a href=\"https://seekingalpha.com/pr/16870552-d-r-horton-raises-offer-17_75-per-share-acquire-75-percent-forestar-forestar-board-declares\" target=\"_blank\">now offering $17.75</a> per share in cash for 75% of Forestar Group (NYSE:<a href='https://seekingalpha.com/symbol/FOR' title='Forestar Group Inc.'>FOR</a>), up from $16.25 previously.</li><li>The Forestar board <a href=\"https://seekingalpha.com/pr/16870481-forestar-board-directors-determines-unsolicited-proposal-d-r-horton-constitutes-superior\" target=\"_blank\">has determined this new</a> offer constitutes a \"superior proposal\" to that of Starwood Capital Group (which has now been raised to $16 per share for the entire company). For now, the Starwood merger deal remains in place.</li><li>FOR&nbsp;<font color='green'>+4.85%</font>&nbsp;premarket to $17.30</li></ul><div class=\"tiny-share-widget\" data-id=\"3275276\" data-linked=\"D.R. Horton lifts bid for Forestar Group\" data-tweet=\"$DHI $DHI $FOR - D.R. Horton lifts bid for Forestar Group https://seekingalpha.com/news/3275276-d-r-horton-lifts-bid-for-forestar-group?source=tweet\" data-url=\"https://seekingalpha.com/news/3275276-d-r-horton-lifts-bid-for-forestar-group\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275274\" data-ts=\"1498223882\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275274-premarket-losers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am</a></h4><ul><li><a href='https://seekingalpha.com/symbol/TOPS' title='TOP Ships Inc.'>TOPS</a>&nbsp;<font color='red'>-40%</font>.</li><li><a href='https://seekingalpha.com/symbol/WKHS' title='Workhorse Group Inc.'>WKHS</a>&nbsp;<font color='red'>-12%</font>.</li><li><a href='https://seekingalpha.com/symbol/BBBY' title='Bed Bath & Beyond Inc.'>BBBY</a>&nbsp;<font color='red'>-11%</font>&nbsp;on&nbsp;<a href=\"https://seekingalpha.com/news/3275155-bed-bath-and-beyond-misses-0_13-misses-revenue\" target=\"_blank\">Q1 earnings</a>&nbsp;miss.</li><li><a href='https://seekingalpha.com/symbol/DRYS' title='DryShips Inc.'>DRYS</a>&nbsp;<font color='red'>-9%</font>.</li><li>BBRY&nbsp;<font color='red'>-8%</font>&nbsp;on&nbsp;<a href=\"https://seekingalpha.com/news/3275223-blackberry-beats-0_04-misses-revenue\" target=\"_blank\">Q1 earnings</a>.</li><li><a href='https://seekingalpha.com/symbol/BLCM' title='Bellicum Pharmaceuticals'>BLCM</a>&nbsp;<font color='red'>-8%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/16870369-bellicum-announces-clinical-data-bpxminus-501-presidential-symposium-22nd-congress-european\" target=\"_blank\">announcing</a> clinical data on BPX-501.</li><li><a href='https://seekingalpha.com/symbol/OCUL' title='Ocular Therapeutix'>OCUL</a>&nbsp;<font color='red'>-7%</font>&nbsp;on being <a href=\"https://seekingalpha.com/news/3275249-premarket-analyst-action-healthcare\" target=\"_blank\">downgraded</a> by Morgan Stanley.</li><li><a href='https://seekingalpha.com/symbol/CLSN' title='Celsion Corporation'>CLSN</a>&nbsp;<font color='red'>-7%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3275133-celsion-backs-away-proposed-direct-equity-offering-shares-24-percent-m-prospects\" target=\"_blank\">cancelling</a> direct equity offering.</li><li><a href='https://seekingalpha.com/symbol/BLUE' title='bluebird bio, Inc.'>BLUE</a>&nbsp;<font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3275274\" data-linked=\"Premarket Losers as of 9:05 am\" data-tweet=\"$TOPS $WKHS $BBBY - Premarket Losers as of 9:05 am https://seekingalpha.com/news/3275274-premarket-losers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3275274-premarket-losers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275273\" data-ts=\"1498223780\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275273-premarket-gainers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am</a></h4><ul><li><a href='https://seekingalpha.com/symbol/SNCR' title='Synchronoss Technologies, Inc.'>SNCR</a>&nbsp;<font color='green'>+35%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3275239-synchronoss-soars-36-percent-acquisition-offer\" target=\"_blank\">acquisition</a> offer.</li><li><a href='https://seekingalpha.com/symbol/CARA' title='Cara Therapeutics Inc.'>CARA</a>&nbsp;<font color='green'>+17%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3275248-cara-receives-breakthrough-therapy-designation-v-cr845-treatment-hemodialysis-patients\" target=\"_blank\">receiving</a> breakthrough therapy designation for I.V. CR845 for the treatment of UP in hemodialysis patients.</li><li><a href='https://seekingalpha.com/symbol/IDRA' title='Idera Pharmaceuticals, Inc.'>IDRA</a> <font color='green'>+6%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/16870140-idera-announces-fda-orphan-drug-designation-imominus-2125-treatment-melanoma\" target=\"_blank\">announcement</a> that FDA has granted orphan drug designation for IMO-2125, an agonist of endosomal Toll-like receptor 9 for the treatment of melanoma Stages IIb to IV.</li></ul><div class=\"tiny-share-widget\" data-id=\"3275273\" data-linked=\"Premarket Gainers as of 9:05 am\" data-tweet=\"$SNCR $CARA $IDRA - Premarket Gainers as of 9:05 am https://seekingalpha.com/news/3275273-premarket-gainers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3275273-premarket-gainers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:16 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275272\" data-ts=\"1498223778\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IDRA\" target=\"_blank\">IDRA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275272-ideras-imominus-2125-orphan-drug-in-u-s-for-advanced-melanoma-shares-ahead-5-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Idera&#39;s IMO-2125 an Orphan Drug in U.S. for advanced melanoma; shares ahead 5% premarket</a></h4><ul><li>Idera Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/IDRA' title='Idera Pharmaceuticals, Inc.'>IDRA</a>) is up&nbsp;<font color='green'>5%</font>&nbsp;premarket on average volume on the heels of its <a href=\"https://seekingalpha.com/pr/16870140-idera-announces-fda-orphan-drug-designation-imominus-2125-treatment-melanoma\" target=\"_blank\">announcement </a>that the FDA has designated Phase 2-stage IMO-2125 an Orphan Drug for the treatment of Stages IIB to IV melanoma.</li><li>IMO-2125 is an agonist of endosomal Toll-like receptor &#40;TLR&#41; 9, a cell surface protein that plays a key role in pathogen recognition and innate immunity.</li><li>Among the benefits of Orphan Drug status in the U.S. is an additional seven-year period of market exclusivity for the indication, if approved.</li></ul><div class=\"tiny-share-widget\" data-id=\"3275272\" data-linked=\"Idera&#39;s IMO-2125 an Orphan Drug in U.S. for advanced melanoma; shares ahead 5% premarket\" data-tweet=\"$IDRA - Idera&#39;s IMO-2125 an Orphan Drug in U.S. for advanced melanoma; shares ahead 5% premarket https://seekingalpha.com/news/3275272-ideras-imominus-2125-orphan-drug-in-u-s-for-advanced-melanoma-shares-ahead-5-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3275272-ideras-imominus-2125-orphan-drug-in-u-s-for-advanced-melanoma-shares-ahead-5-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:16 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275270\" data-ts=\"1498223690\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275270-fatal-london-fire-linked-to-whirlpool-refrigerator\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fatal London fire linked to Whirlpool refrigerator</a></h4><ul>     <li>London Police say that evidence indicates the fatal fire at the Grenfell Tower started in a Whirlpool Hotpoint refrigerator.</li>     <li>At least 79 people were killed in the fire.</li><li>An immediate technical examination of the Hotpoint fridge model has been ordered by U.K. authorities.</li><li>WHR&nbsp;<font color='red'>-0.62%</font>&nbsp;premarket to $193.95.</li>     </ul><div class=\"tiny-share-widget\" data-id=\"3275270\" data-linked=\"Fatal London fire linked to Whirlpool refrigerator\" data-tweet=\"Fatal London fire linked to Whirlpool refrigerator https://seekingalpha.com/news/3275270-fatal-london-fire-linked-to-whirlpool-refrigerator?source=tweet\" data-url=\"https://seekingalpha.com/news/3275270-fatal-london-fire-linked-to-whirlpool-refrigerator\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:14 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275269\" data-ts=\"1498223164\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AVEO\" target=\"_blank\">AVEO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275269-european-ad-com-backs-aveos-tivozanib-for-kidney-cancer-shares-up-57-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">European Ad Com backs AVEO&#39;s tivozanib for kidney cancer; shares up 57% premarket</a></h4><ul><li>AVEO Oncology (NASDAQ:<a href='https://seekingalpha.com/symbol/AVEO' title='AVEO Pharmaceuticals, Inc.'>AVEO</a>) is up&nbsp;<font color='green'>57%</font>&nbsp;premarket on robust volume in response to its <a href=\"https://seekingalpha.com/pr/16870418-aveo-oncology-announces-positive-chmp-opinion-tivozanib-treatment-advanced-renal-cell\" target=\"_blank\">announcement </a>that the European Medicines Agency's Committee for Medicinal Products for Human Use &#40;CHMP&#41; has adopted a positive opinion recommending approval of FOTIVDA (tivozanib) for the treatment of advanced renal cell carcinoma.</li><li>If the European Commission approves the product, a decision expected in ~60 days, AVEO will receive a $4M R&amp;D reimbursement payment from licensee EUSA Pharma as well as $12M in regulatory and reimbursement-related milestones.</li><li>Under their December 2015 agreement, AVEO is eligible for up to $394M in R&amp;D funding and milestones and tiered royalties as high as mid-twenties percent.</li><li>Previously: <a href=\"https://seekingalpha.com/news/2997176-aveo-inks-license-deal-tivozanib-europe-kidney-cancer-shares-31-percent\" target=\"_blank\">AVEO inks license deal for tivozanib in Europe for kidney cancer; shares up 31%</a> (Dec. 21, 2015)</li></ul><div class=\"tiny-share-widget\" data-id=\"3275269\" data-linked=\"European Ad Com backs AVEO&#39;s tivozanib for kidney cancer; shares up 57% premarket\" data-tweet=\"$AVEO - European Ad Com backs AVEO&#39;s tivozanib for kidney cancer; shares up 57% premarket https://seekingalpha.com/news/3275269-european-ad-com-backs-aveos-tivozanib-for-kidney-cancer-shares-up-57-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3275269-european-ad-com-backs-aveos-tivozanib-for-kidney-cancer-shares-up-57-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:06 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275262\" data-ts=\"1498222363\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/C\" target=\"_blank\">C</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275262-sell-side-stress-tests-positive-for-banks\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sell-side: Stress tests a positive for the banks</a></h4><ul><li>via Bloomberg</li><li>Among the winners cited by analysts were Citigroup (NYSE:<a href='https://seekingalpha.com/symbol/C' title='Citigroup Inc.'>C</a>), Bank of America (NYSE:<a href='https://seekingalpha.com/symbol/BAC' title='Bank of America Corporation'>BAC</a>), Zions (NASDAQ:<a href='https://seekingalpha.com/symbol/ZION' title='Zions Bancorporation'>ZION</a>), and Wells Fargo (NYSE:<a href='https://seekingalpha.com/symbol/WFC' title='Wells Fargo & Co.'>WFC</a>). Cutting things maybe a little too close for comfort were State Street (NYSE:<a href='https://seekingalpha.com/symbol/STT' title='State Street Corporation'>STT</a>), Discover (NYSE:<a href='https://seekingalpha.com/symbol/DFS' title='Discover Financial Services'>DFS</a>), AmEx (NYSE:<a href='https://seekingalpha.com/symbol/AXP' title='American Express Company'>AXP</a>), and Morgan Stanley (NYSE:<a href='https://seekingalpha.com/symbol/MS' title='Morgan Stanley'>MS</a>).</li><li>On the regulatory front, the results should add momentum to the president's efforts to ease rules as they can now point to even the Fed as believing the banks are in great shape.</li><li>Morgan Stanley's Betsy Graseck says results are far better than hoped, with excess capital up 17% from last year to $357B. She sees no risk to her estimate of 30% Y/Y increase in capital returns to be announced next week. Her list of names that could top expectations in the CCAR: Northern Trust (NASDAQ:<a href='https://seekingalpha.com/symbol/NTRS' title='Northern Trust Corporation'>NTRS</a>), Wells Fargo, Citigroup, BofA, and JPMorgan (NYSE:<a href='https://seekingalpha.com/symbol/JPM' title='JPMorgan Chase & Co.'>JPM</a>). AmEx and State Street are most at risk. In midcaps, Huntington Bancshares (NASDAQ:<a href='https://seekingalpha.com/symbol/HBAN' title='Huntington Bancshares Incorporated'>HBAN</a>) stands out as well-positioned to top expectations.</li><li>Piper's Kevin Barker would add Zions, and Regions Financial (NYSE:<a href='https://seekingalpha.com/symbol/RF' title='Regions Financial Corporation'>RF</a>) to the list of midcap players standing out on the upside. 2017, he says, is \"the year of the regionals.\"</li><li><a href='https://seekingalpha.com/symbol/XLF' title='Financial Select Sector SPDR ETF'>XLF</a>&nbsp;<font color='green'>+0.45%</font>&nbsp;premarket</li><li>ETFs: <a href='https://seekingalpha.com/symbol/XLF' title='Financial Select Sector SPDR ETF'>XLF</a>, <a href='https://seekingalpha.com/symbol/FAS' title='Direxion Daily Financial Bull 3x Shares ETF'>FAS</a>, <a href='https://seekingalpha.com/symbol/FAZ' title='Direxion Daily Financial Bear 3x Shares ETF'>FAZ</a>, <a href='https://seekingalpha.com/symbol/KRE' title='SPDR S&P Regional Banking ETF'>KRE</a>, <a href='https://seekingalpha.com/symbol/VFH' title='Vanguard Financials ETF'>VFH</a>, <a href='https://seekingalpha.com/symbol/UYG' title='ProShares Ultra Financials ETF'>UYG</a>, <a href='https://seekingalpha.com/symbol/KBE' title='SPDR S&P Bank ETF'>KBE</a>, <a href='https://seekingalpha.com/symbol/IYF' title='iShares U.S. Financials ETF'>IYF</a>, <a href='https://seekingalpha.com/symbol/FNCL' title='Fidelity MSCI Financials Index ETF'>FNCL</a>, <a href='https://seekingalpha.com/symbol/BTO' title='John Hancock Financial Opportunity Fund'>BTO</a>, <a href='https://seekingalpha.com/symbol/IAT' title='iShares U.S. Regional Banks ETF'>IAT</a>, <a href='https://seekingalpha.com/symbol/IYG' title='iShares U.S. Financial Services ETF'>IYG</a>, <a href='https://seekingalpha.com/symbol/KBWB' title='Invesco KBW Bank Portfolio ETF'>KBWB</a>, <a href='https://seekingalpha.com/symbol/QABA' title='First Trust Nasdaq ABA Community Bank ETF'>QABA</a>, <a href='https://seekingalpha.com/symbol/FXO' title='First Trust Financials AlphaDEX ETF'>FXO</a>, <a href='https://seekingalpha.com/symbol/SEF' title='ProShares Short Financials ETF'>SEF</a>, <a href='https://seekingalpha.com/symbol/KBWR' title='Invesco KBW Regional Banking Portfolio ETF'>KBWR</a>, <a href='https://seekingalpha.com/symbol/RYF' title='Invesco S&P Equal Weight Financial ETF'>RYF</a>, <a href='https://seekingalpha.com/symbol/FINU' title='ProShares UltraPro Financials ETF'>FINU</a>, <a href='https://seekingalpha.com/symbol/XLFS' title='Financial Services Select Sector SPDR ETF'>XLFS</a>, <a href='https://seekingalpha.com/symbol/DPST' title='Direxion Daily Regional Banks Bull 3x Shares ETF'>DPST</a>, <a href='https://seekingalpha.com/symbol/KRU' title='ProShares Ultra S&P Regional Banking ETF'>KRU</a>, <a href='https://seekingalpha.com/symbol/FINZ' title='ProShares UltraPro Short Financials ETF'>FINZ</a>, <a href='https://seekingalpha.com/symbol/RWW' title='Oppenheimer Financials Sector Revenue ETF'>RWW</a>, <a href='https://seekingalpha.com/symbol/WDRW' title='Direxion Daily Regional Banks Bear 3x Shares ETF'>WDRW</a>, <a href='https://seekingalpha.com/symbol/KRS' title='ProShares Short S&P Regional Banking ETF'>KRS</a>, <a href='https://seekingalpha.com/symbol/FAZZ' title='Direxion Daily Financial Bear 1x Shares ETF'>FAZZ</a>, <a href='https://seekingalpha.com/symbol/JHMF' title='John Hancock Multifactor Financials ETF'>JHMF</a>, <a href='https://seekingalpha.com/symbol/FTXO' title='First Trust Nasdaq Bank ETF'>FTXO</a>, <a href='https://seekingalpha.com/symbol/FNCF' title='iShares Edge MSCI Multifactor Financials ETF'>FNCF</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3275262\" data-linked=\"Sell-side: Stress tests a positive for the banks\" data-tweet=\"$C $C $BAC - Sell-side: Stress tests a positive for the banks https://seekingalpha.com/news/3275262-sell-side-stress-tests-positive-for-banks?source=tweet\" data-url=\"https://seekingalpha.com/news/3275262-sell-side-stress-tests-positive-for-banks\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:52 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>21&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275258\" data-ts=\"1498221667\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FXC\" target=\"_blank\">FXC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275258-loonie-lower-after-soft-canadian-inflation-print\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Loonie lower after soft Canadian inflation print</a></h4><ul><li><a href=\"http://www.statcan.gc.ca/daily-quotidien/170623/dq170623a-eng.htm?HPA=1\" target=\"_blank\">CPI rose 1.3% Y/Y in May</a>, down from 1.6% in April, and shy of expectations for 1.5%.</li><li>Excluding food and energy, CPI rose 1.4% vs. 1.5% in April, and roughly inline with estimates.</li><li>The loonie (NYSEARCA:<a href='https://seekingalpha.com/symbol/FXC' title='Invesco CurrencyShares Canadian Dollar Trust ETF'>FXC</a>) has tumbled about 40 pips since the news hit, now&nbsp;<font color='red'>down about 0.5%</font>&nbsp;vs. the greenback at $0.7523.</li></ul><div class=\"tiny-share-widget\" data-id=\"3275258\" data-linked=\"Loonie lower after soft Canadian inflation print\" data-tweet=\"$FXC - Loonie lower after soft Canadian inflation print https://seekingalpha.com/news/3275258-loonie-lower-after-soft-canadian-inflation-print?source=tweet\" data-url=\"https://seekingalpha.com/news/3275258-loonie-lower-after-soft-canadian-inflation-print\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:41 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275252\" data-ts=\"1498220300\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARCT\" target=\"_blank\">ARCT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275252-alcobra-updates-on-review-of-strategic-alternatives-shares-ahead-7-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Alcobra updates on its review of strategic alternatives; shares ahead 7% premarket</a></h4><ul> <li>Alcobra (ADHD) <a href=\"https://seekingalpha.com/pr/16870372-alcobra-updates-review-strategic-alternatives\" target=\"_blank\">announces</a> that its Board of Directors is conducting a process to explore and review a range of strategic alternatives focused on maximizing stockholder value from its development assets and cash resources.</li><li>Alcobra has engaged Ladenburg Thalmann &amp; Co. to act as its strategic financial advisor for this process. The Company also intends to streamline its operations in order to preserve its capital and cash resources.</li>   <li>Alcobra&rsquo;s Board has established a Special Committee for the same. Potential alternatives may include acquisition, merger, business combination or any other transaction involving the Company.</li><li>Shares are up&nbsp;<font color='green'>7%</font>&nbsp;premarket on light volume.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3275252\" data-linked=\"Alcobra updates on its review of strategic alternatives; shares ahead 7% premarket\" data-tweet=\"$ARCT - Alcobra updates on its review of strategic alternatives; shares ahead 7% premarket https://seekingalpha.com/news/3275252-alcobra-updates-on-review-of-strategic-alternatives-shares-ahead-7-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3275252-alcobra-updates-on-review-of-strategic-alternatives-shares-ahead-7-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275248\" data-ts=\"1498219707\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CARA\" target=\"_blank\">CARA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275248-cara-receives-breakthrough-therapy-designation-for-i-v-cr845-for-treatment-of-up-in\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cara receives breakthrough therapy designation for I.V. CR845 for the treatment of UP in hemodialysis patients</a></h4><ul><li>Cara Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/CARA' title='Cara Therapeutics Inc.'>CARA</a>) <a href=\"https://seekingalpha.com/pr/16870362-cara-receives-breakthrough-therapy-designation-fda-v-cr845-treatment-chronic-kidney-disease\" target=\"_blank\">announces</a> that the FDA has granted Breakthrough Therapy designation to I.V. <a href=\"http://www.caratherapeutics.com/pipeline-technology/kappa-opioid-receptor-agonists/\" target=\"_blank\">CR845</a> for the treatment of moderate-to-severe <a href=\"https://en.wikipedia.org/wiki/Uremic_pruritus\" target=\"_blank\">uremic pruritus</a> &#40;UP&#41; in <a href=\"https://en.wikipedia.org/wiki/Chronic_kidney_disease\" target=\"_blank\">chronic kidney disease</a> patients undergoing <a href=\"https://en.wikipedia.org/wiki/Hemodialysis\" target=\"_blank\">hemodialysis</a>.</li>     <li>Breakthrough Therapy designation is granted to expedite the development and review process for new therapies addressing serious or life-threatening conditions.</li>  <li>The decision was supported by positive top-line results from Part A of a Phase 2/3 clinical trial of I.V. CR845 in patients with UP. Part A of the trial met its primary endpoint, with a 68% reduction in worst itching scores versus placebo, and its secondary endpoint, with a 100% improvement in quality of life domains versus placebo.</li><li>Shares are up&nbsp;<font color='green'>8%</font>&nbsp;premarket on light volume.</li>        </ul><div class=\"tiny-share-widget\" data-id=\"3275248\" data-linked=\"Cara receives breakthrough therapy designation for I.V. CR845 for the treatment of UP in hemodialysis patients\" data-tweet=\"$CARA - Cara receives breakthrough therapy designation for I.V. CR845 for the treatment of UP in hemodialysis patients https://seekingalpha.com/news/3275248-cara-receives-breakthrough-therapy-designation-for-i-v-cr845-for-treatment-of-up-in?source=tweet\" data-url=\"https://seekingalpha.com/news/3275248-cara-receives-breakthrough-therapy-designation-for-i-v-cr845-for-treatment-of-up-in\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:08 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>38&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275243\" data-ts=\"1498218956\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SKT\" target=\"_blank\">SKT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275243-tanger-factory-down-1_4-after-baml-downgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tanger Factory down 1.4% after BAML downgrade</a></h4><ul><li>Analyst Craig Schmidt piles on the rough run for Tanger Factory (NYSE:<a href='https://seekingalpha.com/symbol/SKT' title='Tanger Factory Outlet Centers, Inc.'>SKT</a>), <a href=\"https://www.streetinsider.com/Analyst+Comments/BofAMerrill+Lynch+Downgrades+Tanger+Factory+Outlet+Centers+%28SKT%29+to+Underperform/13038964.html\" target=\"_blank\">downgrading to Underperform</a> from Neutral. His price target of $25.50 is roughly inline with last night's close.</li><li>SKT is&nbsp;<font color='red'>lower by 28%</font>&nbsp;YTD.</li><li>He expects shares to remain under pressure thanks to increased competition and continued rises in store closings.</li><li>Tanger&nbsp;<font color='red'>down 1.4%</font>&nbsp;premarket to $25.35.</li></ul><div class=\"tiny-share-widget\" data-id=\"3275243\" data-linked=\"Tanger Factory down 1.4% after BAML downgrade\" data-tweet=\"$SKT - Tanger Factory down 1.4% after BAML downgrade https://seekingalpha.com/news/3275243-tanger-factory-down-1_4-after-baml-downgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3275243-tanger-factory-down-1_4-after-baml-downgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:55 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275239\" data-ts=\"1498218334\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNCR\" target=\"_blank\">SNCR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275239-synchronoss-soars-36-on-acquisition-offer\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Synchronoss soars 36% on acquisition offer</a></h4><ul><li>Synchronoss (NASDAQ:<a href='https://seekingalpha.com/symbol/SNCR' title='Synchronoss Technologies, Inc.'>SNCR</a>) shares soaring after an acquisition offer from Siris Capital Group was revealed in a <a href=\"https://seekingalpha.com/filing/3603015\" target=\"_blank\">SEC filing</a>.</li><li>Siris offers $18 per share in cash, a 69% premium on the closing price on Wednesday.</li><li>Synchronoss shares are&nbsp;<font color='green'>up 36.7%</font>&nbsp;premarket.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3275121-synchronoss-requests-lender-extension-quells-cloud-concerns-shares-nearly-20-percent\" target=\"_blank\">Synchronoss requests lender extension, quells cloud concerns; shares up nearly 20%</a> (June 22)</li><li>Correction: updated to correct acquisition price to $18 per share.</li></ul><div class=\"tiny-share-widget\" data-id=\"3275239\" data-linked=\"Synchronoss soars 36% on acquisition offer\" data-tweet=\"$SNCR - Synchronoss soars 36% on acquisition offer https://seekingalpha.com/news/3275239-synchronoss-soars-36-on-acquisition-offer?source=tweet\" data-url=\"https://seekingalpha.com/news/3275239-synchronoss-soars-36-on-acquisition-offer\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:45 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275237\" data-ts=\"1498217794\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/X\" target=\"_blank\">X</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275237-deutsche-buys-dip-in-steel-x-and-aks-move-higher-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Deutsche buys the dip in steel - X and AKS move higher premarket</a></h4><ul><li>U.S. Steel (NYSE:<a href='https://seekingalpha.com/symbol/X' title='United States Steel Corporation'>X</a>) and AK Steel (NYSE:<a href='https://seekingalpha.com/symbol/AKS' title='AK Steel Holding Corp'>AKS</a>) are each upgraded to Buy from Hold at Deutsche Bank.</li><li>Both are<font color='red'> down nearly 40%&nbsp;</font>this year, even after&nbsp;<font color='green'>nice runs higher</font>&nbsp;over the past month.</li><li>X&nbsp;<font color='green'>+2.9%</font>, AKS&nbsp;<font color='green'>+3.8%</font>&nbsp;premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3275237\" data-linked=\"Deutsche buys the dip in steel - X and AKS move higher premarket\" data-tweet=\"$X $X $AKS - Deutsche buys the dip in steel - X and AKS move higher premarket https://seekingalpha.com/news/3275237-deutsche-buys-dip-in-steel-x-and-aks-move-higher-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3275237-deutsche-buys-dip-in-steel-x-and-aks-move-higher-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:36 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>19&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275235\" data-ts=\"1498217343\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CAT\" target=\"_blank\">CAT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275235-caterpillar-lower-on-deutsche-downgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Caterpillar lower on Deutsche downgrade</a></h4><ul><li>Caterpillar (NYSE:<a href='https://seekingalpha.com/symbol/CAT' title='Caterpillar Inc.'>CAT</a>) has <a href=\"https://www.thestreet.com/story/14192879/1/caterpillar-stock-down-in-premarket-trading-by-broker-downgrade.html\" target=\"_blank\">extended</a> its week-to-date loss in premarket trading, <font color='red'>falling 1.3%</font>, after Deutsche Bank cut its rating on stock from Buy to Hold.</li><li>The firm also slashed its PT on shares, to $106 from $121, saying much of the benefit from a nascent recovery in the mining sector has already been priced into the stock.</li></ul><div class=\"tiny-share-widget\" data-id=\"3275235\" data-linked=\"Caterpillar lower on Deutsche downgrade\" data-tweet=\"$CAT - Caterpillar lower on Deutsche downgrade https://seekingalpha.com/news/3275235-caterpillar-lower-on-deutsche-downgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3275235-caterpillar-lower-on-deutsche-downgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275233\" data-ts=\"1498217307\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BB\" target=\"_blank\">BB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275233-blackberry-misses-rev-estimates-announces-share-purchase-shares-down-6_4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BlackBerry misses rev estimates, announces share purchase; shares down 6.4%</a></h4><ul><li>        BlackBerry (BBRY) reports Q1 results that beat EPS estimates by four cents but missed on revenue.</li><li>               Software and services revenues the largest segment with $169M in revenues and about 79% of those sales recurring. The company had 3,000 enterprise customer orders this quarter.&nbsp;</li><li>               Cash: Ended quarter with $2.6B in cash and equivalents. FCF of $860M with OCF of $863M.&nbsp;</li><li>               Share purchase: BlackBerry <a href=\"https://seekingalpha.com/pr/16870382-blackberry-announces-common-share-purchase-program\" target=\"_blank\">separately</a> announces a common share purchase program for up to 31M shares or about 6.4% of the outstanding float.&nbsp;</li><li>               FY18 guidance unchanged: &ldquo;&nbsp;We expect growth at or above the overall market in software and services. We also expect to be profitable on a non-GAAP basis and to generate positive free cash flow for the full year, excluding the benefit of the Qualcomm arbitration award,\" per CEO John Chen.&nbsp;</li><li>               <a href=\"https://seekingalpha.com/pr/16870381-blackberry-reports-profitability-fiscal-2018-first-quarter\" target=\"_blank\">Press release</a>&nbsp;</li><li>                  BlackBerry shares are&nbsp;<font color='red'>down 6.42%</font>&nbsp;premarket. </li><li>Previously: <a href=\"https://seekingalpha.com/news/3275223-blackberry-beats-0_04-misses-revenue\" target=\"_blank\">BlackBerry beats by $0.04, misses on revenue</a> (June 23)</li></ul><div class=\"tiny-share-widget\" data-id=\"3275233\" data-linked=\"BlackBerry misses rev estimates, announces share purchase; shares down 6.4%\" data-tweet=\"$BB - BlackBerry misses rev estimates, announces share purchase; shares down 6.4% https://seekingalpha.com/news/3275233-blackberry-misses-rev-estimates-announces-share-purchase-shares-down-6_4?source=tweet\" data-url=\"https://seekingalpha.com/news/3275233-blackberry-misses-rev-estimates-announces-share-purchase-shares-down-6_4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>181&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275230\" data-ts=\"1498216736\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FINL\" target=\"_blank\">FINL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275230-finish-line-down-post-q1-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Finish Line down post Q1 results</a></h4><ul>     <li>Finish Line (NASDAQ:<a href='https://seekingalpha.com/symbol/FINL' title='The Finish Line, Inc.'>FINL</a>) reports comparable-store sales declined 1.1% in <a href=\"https://seekingalpha.com/pr/16870383-finish-line-reports-first-quarter-fiscal-year-2018-results\" target=\"_blank\">Q1</a>.</li>     <li>Finish Line Macy&rsquo;s sales increased 13.6%.</li>     <li>Gross margin rate down 140 bps to 29.6%.</li>     <li>SG&amp;A expense rate improved 110 bps to 26.2%.</li>     <li>Adjusted operating margin rate flat Y/Y at 3.6%.</li>     <li>Merchandise inventory +5.1% Y/Y to $341.4M.</li>     <li>Store count Y/Y: Finish Line -15 to 571; Branded shops -17 to 375.</li>     <li>For Q2, the company expects comparable store sales to decrease in the low-single digits range.</li>     <li><b>FY2018 Guidance</b>: Comparable-store sales:&nbsp;increase low-single digits;&nbsp;Adjusted EPS: $1.12 to $1.23.</li>     <li>FINL&nbsp;<font color='red'>-1.81%</font>&nbsp;premarket.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3275230\" data-linked=\"Finish Line down post Q1 results\" data-tweet=\"$FINL - Finish Line down post Q1 results https://seekingalpha.com/news/3275230-finish-line-down-post-q1-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3275230-finish-line-down-post-q1-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:18 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3275221\" data-ts=\"1498215471\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RH\" target=\"_blank\">RH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3275221-deutsche-bank-sees-rh-rally-extending\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Deutsche Bank sees RH rally extending</a></h4><ul><li>Deutsche Bank lifts RH (NYSE:<a href='https://seekingalpha.com/symbol/RH' title='RH'>RH</a>) to a Buy rating even after watching shares double in value over the last year.</li><li>RH is expected to boost its buyback activity and sees a reduced impact on revenue from inventory optmization initiatives.</li><li>DB increases its price target on the retailer to a Street high of $66.</li><li>Source: Bloomberg</li><li>RH&nbsp;<font color='green'>+1.89%</font>&nbsp;premarket to $57.72.</li></ul><div class=\"tiny-share-widget\" data-id=\"3275221\" data-linked=\"Deutsche Bank sees RH rally extending\" data-tweet=\"$RH - Deutsche Bank sees RH rally extending https://seekingalpha.com/news/3275221-deutsche-bank-sees-rh-rally-extending?source=tweet\" data-url=\"https://seekingalpha.com/news/3275221-deutsche-bank-sees-rh-rally-extending\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:57 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":43,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}